Developing Meaningful Therapeutic Strategies for Alzheimer's and Parkinson's Diseases
Dale Schenk, CEO, Prothena Corporation
Dr. Dale Schenk, Chief Executive Officer of Prothena, plc, was previously Chief Scientific Officer and Executive Vice President at Elan Pharmaceuticals where he provided the leadership and scientific direction for Elan's research and development programs. Prior to joining Elan, Dr. Schenk was a founding scientist of Athena Neurosciences, which was acquired by Elan Pharmaceuticals.
Dr. Schenk has pioneered the immunotherapeutic approaches for the treatment of amyloidosis, as exemplified for Alzheimer's disease, Parkinson’s disease and light chain (AL) Amyloidosis. Dr. Schenk's work in this area, as well as in early detection, testing and other pathways to these diseases, has led specifically to the most advanced potential treatment approach for Alzheimer's disease. Clinical trials are also currently underway for AL amyloidosis and Parkinon’s disease that utilize immunotherapy.
Dr. Schenk earned his BA and PhD in Pharmacology and Physiology from the University of California, San Diego.